We searched PubMed between Jan 1, 2008, and Jan 1, 2016, for the terms “primary hyperparathyroidism”, “normocalcemic primary hyperparathyroidism”, “parathyroid surgery”, “parathyroid localization”, and “primary hyperparathyroidism international”. The time period for this search covers the years before and after the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism that was held in 2013. We limited the recovered entries to human patients in English. We
SeminarHyperparathyroidism
Introduction
Primary hyperparathyroidism is a common disorder of mineral metabolism that is due to excessive secretion of parathyroid hormone from one or more of the four parathyroid glands. The clinical consequences of abnormally active parathyroid tissue are typically hypercalcaemia and concentrations of parathyroid hormone that are either clearly elevated above the normal range or inappropriately normal in the context of hypercalcaemia.1 Primary hyperparathyroidism predominantly affects women, with studies reporting a female-to-male ratio of approximately 3–4:1.2, 3 Although several different clinical presentations of primary hyperparathyroidism are now commonly recognised, this was not always the case. In the 1930s, Albright first described the hypercalcaemic state caused by primary hyperparathyroidism as a disease of bones and stones.4 Although the clinical presentation of primary hyperparathyroidism has changed since the years of Albright, the central target organs for potential complications of this disorder continue to be the skeleton and kidneys. The typical diagnosis of primary hyperparathyroidism is no longer accompanied by overt skeletal and renal involvement. Rather, detection of skeletal or renal involvement requires proactive testing with technologies that were not available in Albright's day. The change in the clinical phenotype of primary hyperparathyroidism has fostered another dilemma—namely, for whom among the large number of individuals with only biochemical abnormalities associated with primary hyperparathyroidism should parathyroid surgery be recommended? The Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism, held in 2013, addressed this question and other issues.5, 6
Section snippets
Clinical presentation
Asymptomatic primary hyperparathyroidism is the most common presentation in countries, such as the USA, Canada, and Germany, where biochemical screening is routinely implemented. Hypercalcaemia is usually not more than 0·25 mmol/L above the upper limit of the normal range (2·10–2·55 mmol/L). Overt kidney stone disease occurs in less than 20% of patients with primary hyperparathyroidism and radiologically evident bone disease is even less common.7 Conversely, target organ involvement at
North America
In the USA and Canada, primary hyperparathyroidism predominantly presents as an asymptomatic disorder.21 Overall, the prevalence of primary hyperparathyroidism in the USA was estimated at 0·86% in 2008–09.41 Consistent with the change in diagnostic strategies, in Southern California the incidence of primary hyperparathyroidism was reported to have tripled between 1995 and 2010.42 A 60% increase in the incidence of parathyroid cancer over this 15 year period was also reported in the USA.43 Some
Pathophysiology
The secretion and synthesis of parathyroid hormone is controlled by the ambient circulating ionised calcium concentration. Under normal conditions, an increase in circulating ionised calcium concentration, which might not be detected by biochemical methods, will instantly suppress parathyroid hormone secretion. Similarly, an imperceptible reduction in serum calcium concentration will immediately simulate parathyroid hormone secretion. This inverse sigmoidal association between parathyroid
Causes and risk factors
Primary hyperparathyroidism is most commonly due to a single benign parathyroid adenoma (approximately 80% of patients), with multiglandular disease seen in approximately 15–20% of patients.66 Multiglandular disease usually takes the form of four-gland parathyroid hyperplasia, but multiple parathyroid adenomas have also been described. Parathyroid cancer is rare and accounts for well under 1% of all cases of primary hyperparathyroidism.9 In most patients with primary hyperparathyroidism, the
Diagnosis
The albumin-corrected serum calcium concentration is usually elevated. To correct the calcium concentration for serum albumin, the measured serum calcium concentration is adjusted upward by 0·2 mmol/L for every 10 g/L by which the serum albumin is below 40 g/L. Ionised serum calcium concentration can be used for the measurement of serum calcium in centres that are equipped for accurate measurement with an instrument that has a proper ion-sensing electrode, which obviates the need for correction
Evaluation
Biochemical and imaging technology are used to determine whether, and the extent to which, primary hyperparathyroidism has involved the bone and kidney. Blood is obtained to analyse concentrations of serum calcium, phosphorus, parathyroid hormone, 25-hydroxyvitamin D, and bone turnover markers (typically one bone formation and one bone resorption index); a 24-h urine test for calcium and creatinine is also done.1, 42
Skeletal imaging depends on several modalities, the most common being dual
Hypercalcaemic primary hyperparathyroidism
The 15-year observational study by Rubin and colleagues94 indicates that the natural history of asymptomatic hypercalcaemia due to primary hyperparathyroidism can be associated with biochemical and densitometric stability. Many patients who were not candidates for parathyroid surgery at the time of evaluation continued to be stable over the study period. However, a substantial number of patients developed criteria for parathyroid surgery with a tendency for worsening hypercalcaemia and reduced
Acute management
Although primary hyperparathyroidism is considered to be a disorder of mild hypercalcaemia, a presentation of primary hyperparathyroidism with markedly high serum calcium concentrations exists that can be life-threatening. Most often these patients have a history, before their presentation with life-threatening hypercalcaemia, of only mildly elevated serum calcium concentration. Occasionally, patients with life-threatening primary hyperparathyroidism present de novo without any antecedent
Surgical management
Minimally invasive parathyroidectomy under local anaesthesia and conscious sedation is the procedure of choice in many centres, based on the assumption that the parathyroid gland or glands have been identified preoperatively. To identify abnormal parathyroid tissue, preoperative localisation approaches use ultrasound, 99mTc-sestamibi scintigraphy, CT, or four-dimensional CT. Imaging is strongly recommended for patients who are to have parathyroid surgery. The exact modality used depends on
Nutritional guidelines and medical management
Many patients with asymptomatic primary hyperparathyroidism do not have parathyroid surgery but are, instead, managed conservatively. Nutritional guidelines are important for all patients to consider.111 One notion that should be dispelled is that patients with primary hyperparathyroidism should restrict their intake of calcium. Conversely, restriction of calcium intake could provide a further stimulus to abnormal parathyroid tissue to produce parathyroid hormone. National guidelines112
Normocalcaemic primary hyperparathyroidism
The classification of normocalcaemic primary hyperparathyroidism as a primary disorder could be questioned because of the uncertainty related to an unknown secondary stimulus that might foster raised concentrations of parathyroid hormone. Furthermore, consideration of the normal distribution range for any analyte is important. The so-called normal range of parathyroid hormone spans two standard deviations about the mean (eg, 10–65 ng/L), and some patients with normocalcaemic primary
Conclusion
In this Seminar, we have provided an updated account of the new concepts related to the presentation, cause, and management of primary hyperparathyroidism. The disorder presents ongoing challenges as features of its clinical recognition continue to evolve. These changes require regular access to new investigative tools with particular reference to target and off-target manifestations as well as reconsideration of concepts of surgical and non-surgical management.
Search strategy and selection criteria
References (137)
- et al.
Nontraditional manifestations of primary hyperparathyroidism
J Clin Densitom
(2013) - et al.
Asymptomatic primary hyperparathyroidism
J Clin Densitom
(2013) - et al.
Prospective evaluation of quality of life (SF-36v2) and nonspecific symptoms before and after cure of primary hyperparathyroidism (1-year follow-up)
Surgery
(2007) - et al.
Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with “asymptomatic” primary hyperparathyroidism
Surgery
(2009) - et al.
The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record
Surgery
(2013) Role of the calcium-sensing receptor in extracellular calcium homeostasis
Best Pract Res Clin Endocrinol Metab
(2013)- et al.
Cellular actions of PTH. Osteoblasts, osteoclasts, and osteocytes
- et al.
Parathyroids: Morphology and Pathology
- et al.
Benign familial hypocalciuric hypercalcemia
Endocr Pract
(2011) - et al.
Parathyroid carcinoma
Surg Oncol
(2014)
Trabecular bone score is associated with volumetric bone density and microarchitecture as assessed by central QCT and HRpQCT in Chinese American and white women
J Clin Densitom
“Trabecular Bone Score” (TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism
Bone
Silent renal stones in primary hyperparathyroidism: prevalence and clinical features
Endocr Pract
Diagnosis and management of primary hyperparathyroidism—a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism
Arq Bras Endocrinol Metabol
Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK
Clin Endocrinol (Oxf)
Clinical aspects of primary hyperparathyroidism: clinical manifestations, diagnosis, and therapy
Wien Med Wochenschr
Hyperparathyroidism: a common and polymorphic condition as illustrated by seventeen proved cases from one clinic
J Am Med Assoc
Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop
J Clin Endocrinol Metab
Asymptomatic primary hyperparathyroidism
Clinical presentation of primary hyperparathyroidism: a global perspective
Parathyroid carcinoma
Bone disease in primary hyperparathyroidism
Arq Bras Endocrinol Metabol
Renal manifestations of primary hyperparathyroidism
Indian J Endocrinol Metab
Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop
J Clin Endocrinol Metab
Neuromuscular disease in primary hyperparathyroidism
Ann Intern Med
Digestive manifestations of parathyroid disorders
World J Gastroenterol
Parathyroid hormone and the cardiovascular system
Curr Osteoporos Rep
Neuropsychological features in primary hyperparathyroidism: a prospective study
J Clin Endocrinol Metab
Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community
N Engl J Med
Normocalcemic PHPT
Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype
J Clin Endocrinol Metab
Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone?
J Osteoporos
Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women
J Clin Endocrinol Metab
Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study
BMC Endocr Disord
Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and considerations bearing on the need for surgical intervention
J Bone Miner Res
Normocalcaemic, vitamin D-sufficient hyperparathyroidism—high prevalence and low morbidity in the general population: a long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden
Clin Endocrinol (Oxf)
Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy
Endocr Connect
Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations
J Clin Endocrinol Metab
The study of hyperparathyroidism at the Massachusetts General Hospital
N Engl J Med
Patients with surgically cured primary hyperparathyroidism have a reduced quality of life compared with population-based healthy sex-, age-, and season-matched controls
Eur J Endocrinol
Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism
World J Surg
Lower quality of life in longstanding mild primary hyperparathyroidism
Arq Bras Endocrinol Metabol
Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism
J Clin Endocrinol Metab
Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial
J Clin Endocrinol Metab
Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial
J Clin Endocrinol Metab
No beneficial effects of vitamin D supplementation on muscle function or quality of life in primary hyperparathyroidism: results from a randomized controlled trial
Eur J Endocrinol
Health-related quality of life after successful surgery for primary hyperparathyroidism: no additive effect from vitamin D supplementation: results of a double-blind randomized study
Eur J Endocrinol
Development of a new tool for assessing health-related quality of life in patients with primary hyperparathyroidism
Health Qual Life Outcomes
Incidence and prevalence of primary hyperparathyroidism in a racially mixed population
J Clin Endocrinol Metab
Cited by (362)
Osteoporosis management-current and future perspectives – A systemic review
2024, Journal of OrthopaedicsHyperparathyroidism in a hemodialyzed patient
2024, Joint Bone SpinePrimary hyperparathyroidism
2024, Best Practice and Research: Clinical Endocrinology and MetabolismClinical applications of smart wearable sensors
2023, iScience